Is Entero Healthcar overvalued or undervalued?

As of 22 August 2025, Entero Healthcare's valuation grade has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently assessed as undervalued. Key ratios include a PE ratio of 52.27, an EV to EBITDA of 28.35, and a PEG ratio of 0.37, which suggests that the stock may be undervalued relative to its growth potential.
In comparison with peers, Entero Healthcare's PE ratio is notably higher than TCS at 22.42 and Infosys at 22.67, while its EV to EBITDA is also above TCS's 15.8 and Infosys's 14.88. Despite its high valuation metrics, the low PEG ratio indicates that the stock may offer growth at a reasonable price compared to its peers. Additionally, Entero's recent stock performance has outpaced the Sensex over the past week and month, reinforcing the notion of its undervaluation in the current market context.